JOHNSON & JOHNSON · 2026-10-30 · Importance 44 · Surprise 24
The report says Johnson & Johnson’s sales growth has accelerated over the past year despite competition for STELARA. Newer medicine TREMFYA has contributed to growth in the Innovative Medicine segment. The article also reports that sales growth slowed for two consecutive quarters, indicating a moderation in the broader growth trend.
Key facts
Johnson & Johnson's sales growth slowed for two consecutive quarters amid competition for STELARA. source
Johnson & Johnson's newer medicines, including Tremfya, contributed to sales growth while the company faced competition for STELARA. source